Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Total cellular protein presence of the transcription factor IRF8 does not necessarily correlate with its nuclear presence.

Minderman H, Maguire O, O'Loughlin KL, Muhitch J, Wallace PK, Abrams SI.

Methods. 2017 Jan 1;112:84-90. doi: 10.1016/j.ymeth.2016.08.011. Epub 2016 Aug 28.


Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus.

Maguire O, Tornatore KM, O'Loughlin KL, Venuto RC, Minderman H.

Cytometry A. 2013 Dec;83(12):1096-104. doi: 10.1002/cyto.a.22401. Epub 2013 Oct 17.


Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells.

Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ Jr, Odunsi K, Bankert RB.

Cancer Immun. 2013 Jul 15;13:14. Print 2013.


Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells.

Melchjorsen J, Risør MW, Søgaard OS, O'Loughlin KL, Chow S, Paludan SR, Ellermann-Eriksen S, Hedley DW, Minderman H, Østergaard L, Tolstrup M.

J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):265-75. doi: 10.1097/QAI.0b013e3182185276.


Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia.

Burcu M, O'Loughlin KL, Ford LA, Baer MR.

Leukemia. 2008 Nov;22(11):2110-5. doi: 10.1038/leu.2008.87. Epub 2008 Apr 17. No abstract available.


Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.

Wetzler M, Brady MT, Tracy E, Li ZR, Donohue KA, O'Loughlin KL, Cheng Y, Mortazavi A, McDonald AA, Kunapuli P, Wallace PK, Baer MR, Cowell JK, Baumann H.

Clin Cancer Res. 2006 Nov 15;12(22):6817-25.


The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.

Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR.

Invest New Drugs. 2007 Apr;25(2):115-22. Epub 2006 Oct 28.


Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.

Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O'Loughlin KL, Ambudkar SV, Baer MR.

Cancer Chemother Pharmacol. 2007 Jul;60(2):179-88. Epub 2006 Oct 10.


Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.

Minderman H, O'Loughlin KL, Smith PF, Pendyala L, Greco WR, Sweeney KG, Ford LA, Wetzler M, Baer MR.

Cancer Chemother Pharmacol. 2006 Jan;57(1):73-83. Epub 2005 Nov 5.


In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells.

Minderman H, Conroy JM, O'Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR.

Mol Cancer Ther. 2005 Jun;4(6):885-900.


Cyclosporin A is a broad-spectrum multidrug resistance modulator.

Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR.

Clin Cancer Res. 2005 Mar 15;11(6):2320-6.


Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.

Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR, Wetzler M, Ross DD, Baer MR.

Br J Haematol. 2004 Nov;127(4):392-8.


Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.

Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD, Baer MR.

Leukemia. 2004 Jul;18(7):1252-7.


Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia.

Suvannasankha A, Minderman H, O'Loughlin KL, Sait SN, Stewart CC, Greco WR, Baer MR.

Leuk Res. 2004 May;28(5):449-55.


Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR.

Cancer Chemother Pharmacol. 2004 May;53(5):363-9. Epub 2004 Jan 27.


Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ.

Mol Cancer Ther. 2003 Nov;2(11):1195-205. Erratum in: Mol Cancer Ther. 2004 Jan;3(1):101. Brooks, Tracy [corrected to Brooks, Tracy A].


Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA.

Blood. 2002 Aug 15;100(4):1224-32.


Flow cytometric analysis of breast cancer resistance protein expression and function.

Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR.

Cytometry. 2002 Jun 1;48(2):59-65.


Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia.

Bunworasate U, Arnouk H, Minderman H, O'Loughlin KL, Sait SN, Barcos M, Stewart CC, Baer MR.

Blood. 2001 Dec 1;98(12):3492-4.


Acute myeloid leukemia in the setting of low dose weekly methotrexate therapy for rheumatoid arthritis.

Kolte B, Baer AN, Sait SN, O'Loughlin KL, Stewart CC, Barcos M, Wetzler M, Baer MR.

Leuk Lymphoma. 2001 Jul;42(3):371-8.


Supplemental Content

Loading ...
Support Center